rs12130603 - KAZN, KAZN-AS1
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome‐Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β‐Blockers - Unknown journal (n.d.) · Unknown authors · PubMed 29478026
ABSTRACT: Background For many indications, the negative chronotropic effect of β‐blockers is important to their efficacy, yet the heart rate (HR) response to β‐blockers varies. Herein, we sought to use a genome‐wide association approach to identify novel single nucleotide polymorphisms (SNPs) associated with HR response to β‐blockers. Methods and Results We first performed 4 genome‐wide association analyses for HR response to atenolol (a β1‐adrenergic receptor blocker) as: (1) monotherapy or (2) add‐on therapy, in 426 whites and 273 blacks separately from the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) study. A meta‐analysis was then performed between the genome‐wide association analysis performed in PEAR atenolol monotherapy and add‐on therapy,
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Drug interactions
-
atenolol dosing response Moderate
The rs12130603 C allele is associated with altered heart rate response to beta blocker therapy.
If prescribed atenolol, discuss this genetic variant with your physician for potential dosing optimization.